BioVision

Doramapimod

STRUCTURE:

ALTERNATE NAME: 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-

yl-ethoxy)-naphthalen-1-yl]-urea; BRRB 796

CATALOG #: 1954-5, 25

AMOUNT: 5 mg, 25 mg

J. J. O

MOLECULAR FORMULA: $C_{31}H_{37}N_5O_3$

MOLECULAR WEIGHT: 527.66

CAS NUMBER: 285983-48-4

APPEARANCE: White to off-white solid

SOLUBILITY: DMSO (~50 mg/ml) or EtOH (~ 30 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C. Protect from light

DESCRIPTION: Cell-permeable. A potent protein kinase inhibitor with a >330-

fold selectivity for p38 MAPK compared with 12 other protein kinases. In contrast to other p38 MAPK inhibitors (e.g., SB203580), doramapimod prevents both the kinetic activity and phosphorylation of p38 MAPK by binding to the ATP pocket as well as to a novel allosteric binding site on p38

MAPK.

REFERENCE: Fabian, M.A., et al. (2005). Nat. Biotechnol. 23, 329-336.

HANDLING: Do not take internally. Wear gloves and mask when handling

the product! Avoid contact by all modes of exposure.

FOR RESEARCH USE ONLY! Not to be used on humans.

RELATED PRODUCTS:

- PD1834352 (CI-1040) (Cat. No. 1585-1,5,25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- Sorafenib (Cat. No. 1594-25, 100)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1,5)